📰 Complete Response News
Page 11 - Complete Response News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Complete Response. Real-time updates on events, politics, business and more.
December 2, 2021
Focused medicines company delivering strong operational performanceBuilding depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint Confident to grow
November 23, 2021
Aadi Bioscience Announces FDA Approval of its First Product FYARRO™ for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa) - read this article along with other careers information, tips and advice on BioSpace
November 4, 2021
/PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address...
November 4, 2021
/PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address...
October 25, 2021
Data presented by Professor Christophe Le Tourneau at the 2021 Annual Meeting of the American Society for Radiation Oncology First survival data from Phase I Dose Expansion in tough-to-treat elderly
October 25, 2021
Data presented by Professor Christophe Le Tourneau at the 2021 Annual Meeting of the American Society for Radiation Oncology First survival data from Phase I Dose Expansion in tough-to-treat... | October 25, 2021
October 13, 2021
The FDA has assigned a PDUFA target date of March 11, 2022 for the New Drug Application for Adlarity.
October 11, 2021
/PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that the U.S. Food and Drug Administration (FDA)...
October 11, 2021
/PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that the U.S. Food and Drug Administration (FDA)...